Evercore ISI Downgrades Health Catalyst (NASDAQ:HCAT) to Inline

Evercore ISI lowered shares of Health Catalyst (NASDAQ:HCAT) from an outperform rating to an inline rating in a report issued on Wednesday,Briefing.com Automated Import reports.

A number of other brokerages also recently weighed in on HCAT. Stifel Nicolaus reduced their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday, February 27th. Stephens decreased their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company dropped their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Royal Bank of Canada lowered their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Finally, KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.73.

Health Catalyst Price Performance

HCAT stock traded down $0.26 during mid-day trading on Wednesday, hitting $3.76. The stock had a trading volume of 239,719 shares, compared to its average volume of 616,643. The firm has a fifty day simple moving average of $4.72 and a 200 day simple moving average of $6.57. Health Catalyst has a 52 week low of $3.60 and a 52 week high of $9.24. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $263.92 million, a P/E ratio of -2.78 and a beta of 1.43.

Insider Buying and Selling at Health Catalyst

In related news, General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the sale, the general counsel now owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of Health Catalyst stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the sale, the insider now owns 92,260 shares of the company’s stock, valued at approximately $535,108. The trade was a 6.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,030 shares of company stock valued at $263,269. 2.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

A number of large investors have recently bought and sold shares of HCAT. Centiva Capital LP acquired a new stake in shares of Health Catalyst in the 3rd quarter valued at about $324,000. Quadrature Capital Ltd bought a new stake in shares of Health Catalyst during the third quarter valued at approximately $84,000. State Street Corp raised its position in shares of Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Health Catalyst by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after purchasing an additional 66,896 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Health Catalyst by 5.8% in the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock valued at $857,000 after purchasing an additional 5,687 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.